s for, predict future resistance? a. Oncotype Dx is a category 1 recommendation and thus the gold standard. It assesses 21 different genes and provides both prognostic and predictive information. For example, it is clinically used to determine what patients will benefit from chemotherapy bui is not necessarily used to determine resistance. However, it may be useful to assess these core 21 genes. There are other assays as well, such as MammaPrint, Prosigna, EndoPredict, and BCI. Do these assays test for any unique genes not already covered by Oncotype, that **Oncotype DX's 21-gene panel provides prognostic information about recurrence risk but was not specifically designed to predict resistance to therapy** , though its molecular drivers offer some insights into potential resistance mechanisms. The other commercially available assays (MammaPrint, Prosigna, EndoPredict, and Breast Cancer Index) evaluate different gene sets that may capture complementary aspects of tumor biology relevant to treatment response.

## Oncotype DX and Resistance Prediction

**Oncotype DX is primarily predictive of chemotherapy benefit rather than resistance per se. ** The TAILORx and RxPONDER trials demonstrated that patients with low recurrence scores (RS [1]

However, this reflects initial chemosensitivity rather than acquired resistance mechanisms. **The molecular drivers of the Oncotype DX recurrence score reveal important limitations for resistance prediction. ** In contrast to common understanding, **RS is determined more strongly by estrogen-related features (ρ = -0.79) and only weakly by proliferation markers (ρ = 0.36)** .[2]

The estrogen module explains only 0.6% of variance in other prognostic tests, while the proliferation module explains 72.5% of ROR's variance.[2]

This means Oncotype DX may miss proliferation-driven resistance mechanisms that are better captured by other assays. Notably, **race-based disparities in outcomes exist even with similar RS values** . In TAILORx, Black patients with RS 11-25 had significantly worse outcomes compared to White patients for invasive disease-free survival and distant recurrence-free interval, yet showed no evidence of chemotherapy benefit.[3]

This suggests that the 21- gene panel may not fully capture all resistance mechanisms across diverse populations.

## Unique Genes in Other Assays

**Each assay evaluates distinct gene sets that may provide complementary information about resistance:** **MammaPrint (70-gene assay):** Evaluates a broader genomic profile than Oncotype DX and is prognostic for distant recurrence in both node-negative and node-positive disease.[1]

The MINDACT trial showed that patients with high clinical risk but low genomic risk had 8-year distant metastasis-free survival of 89.4% without chemotherapy.[1]

However, **MammaPrint has not been validated to predict chemotherapy benefit** , limiting its utility for resistance prediction.[1] may predict resistance? **Prosigna (PAM50, 50-gene assay):** **Is determined largely by proliferative features (72.5% of variance explained by proliferation module)** , which may better capture proliferation-driven resistance mechanisms than Oncotype DX.[2]

Prosigna provides intrinsic subtype classification (luminal A, luminal B, HER2-enriched, basal- like) and risk of recurrence scores.[1]

In node-positive patients with low ROR scores treated with endocrine therapy alone, distant recurrence risk was less than 3.5% at 10 years.[1]

Like MammaPrint, it has not been validated to predict chemotherapy benefit.[1] **EndoPredict (12-gene assay):** **50.0% of its variance is accounted for by the proliferation module and 20.2% by the estrogen module** , providing a different balance than Oncotype DX.[2]

The assay is prognostic in patients treated with both endocrine and chemo-endocrine therapy.[1]

In low-risk patients, distant recurrence risk was 4% at 10 years (ABCSG 6/8) and 5.6% in node-positive patients (TransATAC).[1] **Breast Cancer Index (BCI):** **54.3% of variance explained by proliferation and only 2.7% by estrogen features** .[2]

Uniquely, BCI is **predictive of benefit from extended adjuvant endocrine therapy** .[1]

Patients with BCI (H/I) high demonstrated significant improvements in disease-free survival when adjuvant endocrine therapy was extended in secondary analyses of MA.17, Trans-aTTom, and IDEAL trials.[1]

This addresses late resistance to endocrine therapy specifically.

## Potential Utility for Resistance Prediction

**The core 21 genes in Oncotype DX could theoretically inform resistance risk, but with important caveats:** The genes include proliferation markers (Ki-67, STK15, Survivin, Cyclin B1, MYBL2), invasion genes (MMP11, CTSL2), HER2 group (GRB7, HER2), and estrogen group (ER, PGR, BCL2, SCUBE2).[2]

However, since **RS correlates weakly with proliferation (the primary driver of most resistance mechanisms discussed earlier in our conversation)** , it may underestimate resistance risk in highly proliferative tumors. **Gene expression signatures can change after neoadjuvant treatment** , with proliferation-associated genes downregulated in post-treatment ER+ tumors but not in triple-negative breast cancer, and extracellular matrix genes upregulated across subtypes.[4]

This suggests that **serial assessment of gene expression profiles could potentially track emerging resistance** , though this is not current standard practice. **The benefit of testing these assays for predicting resistance to specific targeted therapies is unknown. ** The NCCN guidelines note that the benefit of BCI testing for extended endocrine therapy is unknown in patients who received ovarian function suppression, CDK4/6 inhibitors, or olaparib in addition to adjuvant endocrine therapy.[1]

This limitation likely extends to other assays and resistance scenarios. Would you like me to summarize emerging research on dynamic or serial gene expression profiling during treatment to detect early molecular changes that might predict impending resistance, or discuss how integration of multiple assays might provide more comprehensive resistance risk assessment? Given the limitations of current static gene expression assays in predicting therapy resistance, I would suggest you consider reviewing the latest evidence on dynamic or serial gene expression profiling—specifically, how changes in tumor gene signatures during or after treatment may signal emerging resistance. Would you like me to summarize key studies or ongoing trials investigating this approach in breast cancer?



### References
1. Breast Cancer. National Comprehensive Cancer Network. Updated 2025-10-16.
2. Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. Buus R, Sestak I, Kronenwett R, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2021;39(2):126-135. doi:10.1200/JCO.20.00853.
3. Prognostic and Predictive Insights From Genomic Assays for Breast Cancer in Diverse Populations. Abdou Y , Kantor O, Racz J, et al. JAMA Oncology. 2025;11(6):655-663. doi:10.1001/jamaoncol.2025.0178.
4. Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer. Marín-Liébana S, Llor P , Serrano-García L, et al. Cancers. 2025;17(9):1482. doi:10.3390/cancers17091482. 12.